Boundless Bio Net Income

The latest net income for BOLD is $-64M as of June 2026. That compares with $-64M in the prior-year period — up 0.6% year over year. That is below the sector sector average of $130M. Investors often review this figure alongside Boundless Bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, BOLD's net income moved from $-64M to $-64M — a 0.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Boundless Bio's operating scale or balance-sheet position.

Against its sector companies, BOLD currently prints $-64M for net income, while the sector average sits near $130M. That is roughly 148.8% below the sector mean. Large gaps often invite a closer look at Boundless Bio's growth, margins, and balance sheet.

A net income figure of $-64M for BOLD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $130M. Explore the charts below for those layers of context.

After noting BOLD's net income ($-64M), review year-over-year change from $-64M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.